Recent revelations unfold a troubling connection between the Trump administration and Bayer, the German chemical giant, amid an ongoing Supreme Court battle over the glyphosate herbicide, Roundup. Internal records indicate that top officials at the Environmental Protection Agency (EPA) held a meeting with Bayer’s CEO, Bill Anderson, last year to discuss litigation strategies just before the administration took significant actions that bolstered Bayer’s legal position.
Meeting with High-Level Officials
On 17 June 2025, Bill Anderson met with senior EPA officials, including Lee Zeldin, the agency’s administrator, and Nancy Beck, currently the principal deputy assistant administrator for the Office of Chemical Safety and Pollution Prevention. This meeting appeared to focus on “litigation” and “Supreme Court action” concerning glyphosate, a herbicide linked to numerous cancer claims from users. Thousands of lawsuits have emerged, with plaintiffs alleging that Bayer failed to adequately warn them of the potential cancer risks associated with glyphosate-based products.
Bayer’s strategy hinges on persuading the Supreme Court that if the EPA does not mandate a cancer warning for glyphosate, the company should not be held liable for failing to provide such a warning. While one appellate court has sided with Bayer, this argument has faced rejection in multiple other courts, including from the Biden administration’s solicitor general.
Administration’s Support for Bayer
Following the June meeting, the Trump administration exhibited a series of actions supportive of Bayer. This culminated in a 1 December 2025 filing with the Supreme Court by D. John Sauer, the solicitor general appointed by Trump, advocating for the court to hear Bayer’s case. The Supreme Court subsequently scheduled a hearing for 27 April 2026.
Further backing came on 18 February 2026 when the White House invoked the Defense Production Act to safeguard glyphosate production, providing what was described as “immunity” for glyphosate manufacturers like Bayer. On 2 March 2026, Sauer submitted an amicus brief to the Supreme Court, demonstrating full governmental support for Bayer’s position.
Ethical Implications of Corporate Influence
Critics are increasingly alarmed by the implications of these meetings and subsequent actions. Nathan Donley, director of environmental health science at the Center for Biological Diversity, expressed concern over the apparent prioritisation of corporate interests over public health. “It’s becoming abundantly clear that the political appointees at the EPA are more invested in protecting pesticide company profits than the health of Americans,” he stated.
Legal experts have raised eyebrows at the prospect of a major pesticide company engaging in direct discussions with the EPA regarding liability limitations. Whitney Di Bona, a consumer safety advocate, remarked, “We should also ask whether the agency gave the same chance to speak to the thousands of people who say they got cancer after using Roundup.” The disparity in access raises questions about the fairness of regulatory processes, particularly when corporate lobbying appears to overshadow the voices of affected individuals.
Calls for Transparency and Accountability
The implications of these revelations have prompted advocates to call for greater transparency in the regulatory process. Zen Honeycutt, founder of Moms Across America, highlighted the historical context of chemical companies exerting influence over regulatory bodies. “Coercion by chemical companies on our regulatory agencies is nothing new,” she asserted, pointing to the lack of progress on calls to restrict or ban hazardous pesticides despite numerous meetings with EPA officials.
Bayer, in response to the scrutiny, has characterised the meeting as a routine aspect of the regulatory process, asserting it has maintained transparency regarding its legal challenges. However, critics argue that the nature of such interactions raises fundamental questions about the integrity of the regulatory framework and the extent to which corporate interests can shape policy decisions.
Why it Matters
The unfolding narrative surrounding Bayer and the Trump administration underscores a critical issue: the intersection of corporate influence and public health policy. As regulatory agencies grapple with the implications of their decisions, the potential for significant health consequences looms large over the thousands of individuals affected by glyphosate. This case exemplifies the urgent need for accountability and transparency in regulatory processes, ensuring that public health considerations are not overshadowed by corporate lobbying. The outcome of this legal battle could have far-reaching implications not only for Bayer but also for consumer safety and environmental health standards across the United States.
